{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["9(32)"],"submitter":["Cui L"],"pubmed_abstract":["Currently available vaccines against COVID-19 showed high efficacy against the original strain of SARS-CoV-2 but progressively lower efficacy against new variants. In response to emerging SARS-CoV-2 strains, we propose chimeric DNA vaccines encoding the spike antigen, including a combination of selected key mutations from different variants of concern. We developed two DNA vaccines, pVAX-S1-TM-D614G and pVAX-S1-TM-INDUK (INDUK), encoding the SARS-CoV-2 S1 spike subunit in fusion with the transmembrane region that allows protein trimerization as predicted by <i>in silico</i> analysis. pVAX-S1-TM-D614G included the dominant D614G substitution, while the chimeric vaccine INDUK contained additional selected mutations from the Delta (E484Q and L452R) and Alpha (N501Y and A570D) variants. Consid"],"journal":["ACS omega"],"pagination":["34624-34635"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11325517"],"repository":["biostudies-literature"],"pubmed_title":["Enhancing Immune Responses against SARS-CoV-2 Variants in Aged Mice with INDUK: A Chimeric DNA Vaccine Encoding the Spike S1-TM Subunits."],"pmcid":["PMC11325517"],"pubmed_authors":["Renzi S","Pozzi D","Pesce L","Marchini C","Cui L","Quagliarini E","Cardarelli F","Wang J","Bartozzi B","Xiao S","Orlando F","Amici A","Provinciali M","Giacconi R","Galeazzi R","Malavolta M","Caracciolo G","Giorgini G"],"additional_accession":[]},"is_claimable":false,"name":"Enhancing Immune Responses against SARS-CoV-2 Variants in Aged Mice with INDUK: A Chimeric DNA Vaccine Encoding the Spike S1-TM Subunits.","description":"Currently available vaccines against COVID-19 showed high efficacy against the original strain of SARS-CoV-2 but progressively lower efficacy against new variants. In response to emerging SARS-CoV-2 strains, we propose chimeric DNA vaccines encoding the spike antigen, including a combination of selected key mutations from different variants of concern. We developed two DNA vaccines, pVAX-S1-TM-D614G and pVAX-S1-TM-INDUK (INDUK), encoding the SARS-CoV-2 S1 spike subunit in fusion with the transmembrane region that allows protein trimerization as predicted by <i>in silico</i> analysis. pVAX-S1-TM-D614G included the dominant D614G substitution, while the chimeric vaccine INDUK contained additional selected mutations from the Delta (E484Q and L452R) and Alpha (N501Y and A570D) variants. Consid","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Aug","modification":"2026-06-03T00:39:57.447Z","creation":"2025-04-19T13:51:55.688Z"},"accession":"S-EPMC11325517","cross_references":{"pubmed":["39157118"],"doi":["10.1021/acsomega.4c03285"]}}